Aims We recently demonstrated that aldosterone induces a non-genomic vasoconstrictor effect on rat coronary arterioles and that this effect was blocked by angiotensin II type 1 receptor (AT 1 ) blockers. Intracellular transglutaminase enhances AT 1 signalling by cross-linking AT 1 homodimers. The purpose of this study was to confirm the AT 1 -dependency of the vasoconstrictor effect of aldosterone using AT 1 a knockout (AT 1 aKO) mice and to investigate the role of intracellular transglutaminase and AT 1 dimerization in this effect.
Introduction
In addition to stimulation of NaCl transport in the renal distal tubules and collecting ducts, aldosterone promotes cardiac hypertrophy, fibrosis, and vascular inflammation. [1] [2] [3] Aldosterone exerts these classical effects through binding to the mineralocorticoid receptor (MR), which is translocated into the nucleus where it initiates the transcription of target genes. In contrast to these genomic actions of aldosterone, rapid non-genomic effects of aldosterone have also been demonstrated. These effects occur within seconds or in a few minutes and are not blocked by either spironolactone or inhibitors of transcription and protein synthesis, suggesting that they are independent of the MR. 4 It was recently reported that aldosterone shows rapid vasomotor effects in rabbit afferent and efferent arterioles, canine coronary arteries, and rat mesenteric arteries. [5] [6] [7] A rapid action of aldosterone has also been reported in humans. [8] [9] [10] Although these rapid non-genomic effects of aldosterone have been said to be mediated via a putative membrane receptor, the precise mechanism underlying these effects remains unclear.
It was reported that aldosterone increases the number of angiotensin II type 1 (AT 1 ) receptors and their responsiveness 11, 12 ; moreover, aldosterone-induced cardiac fibrosis is abolished by an AT 1 receptor blocker. 13 These findings raise the possibility that aldosterone interacts with AT 1 receptor, either directly or indirectly. We recently demonstrated that aldosterone induces a rapidly occurring vasoconstrictor effect in isolated rat coronary arterioles, and this effect is inhibited by AT 1 receptor blockers but not by spironolactone. 14 The AT 1 receptor is usually activated by angiotensin II, but is also activated by mechanical stimuli, such as stretch, independently of angiotensin II, in cardiomyocytes. 15 A recent study demonstrated that dimerization of AT 1 receptors cross-linked by intracellular transglutaminase enhances signalling downstream of these receptors in human monocytes. 16 In the present study, using mesenteric arterioles isolated from wild-type (WT) and AT 1 a knockout (AT 1 aKO) mice, we investigated whether AT 1 receptors participate in the vasoconstrictor effect of aldosterone, and whether receptor dimerization is involved.
Methods
This investigation conforms with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All experimental procedures were carried out in accordance with the Guidelines for Animal Experiments of Hirosaki University Graduate School of Medicine.
Animals
Male C57BL/6J WT mice and AT 1 aKO mice aged 15-25 weeks were used. AT 1 aKO mice were kindly provided by Tanabe Seiyaku Co., Ltd (Osaka, Japan) and have been characterized previously. 17 All mice were kept in a specific pathogen-free facility under controlled temperature (23 + 18C) and humidity (60%), with a 12 h artificial light and dark cycle, in the Institute for Animal Experiments at our institution. Animals were given free access to standard laboratory mouse chow and tap water.
Preparation for experiments
All experiments were carried out according to the methods established by Duling et al. 18 and Kuo et al. 19 WT and AT 1 aKO mice were anaesthetized with sodium pentobarbital (50 mg/kg, i.p.) and the mesenteric arteries were removed and immediately placed in 48C physiological salt solution (PSS) containing (in mmol/L) NaCl 145.0, KCl 4.7, CaCl 2 2.0, MgSO 4 1.17, NaHPO 4 1.2, glucose 5.0, pyruvate 2.0, ethylenediaminetetraacetic acid 0.02, and 3-morpholinopropanesulfonic acid 3.0. The mesenteric arterioles (60-160 mm in internal diameter) were dissected from the surrounding intestinal tissue under cold (58C) PSS containing albumin at pH 6.9. Each isolated microvessel was then transferred for cannulation into a Lucite vessel chamber containing albumin-PSS (pH 7.4) equilibrated with room air at ambient temperature. Both ends of each vessel were cannulated with micropipettes filled with albumin-PSS. Cannulated vessels were then securely tied to micropipettes using 11-0 ophthalmic sutures (Alcon).
Drugs
Drugs and chemicals were purchased from SIGMA-ALDRICH Japan K.K. (Tokyo, Japan) except where specifically stated. Valsartan and benazepril were gifts from Novartis Pharma K.K. (Tokyo, Japan). Candesartan (CV-11974) was a gift from Takeda Chemical Industries, Ltd (Osaka, Japan). Eplerenone was purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan).
Instrumentation
After cannulation, vessels were transferred to the stage of an inverted microscope (IX70, Olympus) coupled to a CCD camera (CS330, Olympus) and video micrometer (Microcirculation Research Institute, Texas A&M University Health Science Center).
The micropipettes were connected to an independent pressure reservoir system, and intraluminal pressures were measured through the side arms of the two reservoir lines by low-volume-displacement strain-gauge transducers. The isolated vessels were pressurized without flow by setting both reservoirs at the same hydrostatic level. The internal diameters of each vessel were measured throughout the experiment by video microscopic techniques, as described previously.
14,19
Experimental protocols in isolated vessel studies
Each cannulated vessel was bathed in albumin-PSS and equilibrated with room air, and the temperature was maintained at 36-378C. Vessels were maintained at their in situ length, and allowed to develop basal tone at 60 cmH 2 (10 24 M) on the aldosterone-mediated effects on mesenteric arteriole diameter, the effects of aldosterone on mesenteric arteriolar diameter were observed before and after treatments with these inhibitors. All drugs were added to the vessel bath 30 min before the administration of aldosterone, and were present throughout the study. To determine any additional effect of aldosterone on angiotensin II-induced vascular responses, the effect of angiotensin II alone and the combined effects of angiotensin II and aldosterone were examined in the same vessels. To investigate whether another steroid hormone could exert a vasoconstrictor effect similar to that of aldosterone, the effects of incremental doses of hydrocortisone (10 213 to 10 26 M) on arteriolar diameter were examined. At the end of each experiment, the vasoconstrictor response to 40 mM KCl was estimated to confirm biological reactivity. Vessels with constrictor responses ,30% of the baseline diameter were excluded from the study.
Endothelial denudation
To assess the role of the endothelium in the effect of aldosterone, the endothelium was mechanically denuded by passing air through the lumen. 20 The absence of a dilator response to acetylcholine (10 -5 mol/L) after pre-constriction with 40 mM KCl was examined to confirm the adequacy of denudation. Full dilation in response to sodium nitroprusside (10 -6 mol/L) was used to confirm that the vascular smooth muscle cells (VSMCs) remained functionally intact after denudation. The diameter changes in endothelium-intact and endothelial-denuded arterioles in response to acetylcholine were 84.2 + 2.2 and 7.5 + 6.3%, respectively, relative to the full dilator response to sodium nitroprusside (10 -4 mol/L). All other experiments of contraction studies were performed using endothelium-intact arterioles.
Protein extraction
Isolated mesenteric arteriole networks from WT mice were washed in cool phosphate-buffered saline (PBS), and equilibrated in albumin-PSS for 30 min at 378C, followed by treatment with or without aldosterone (10 27 M) for 10 min. Some preparations treated with aldosterone were pre-treated with 5Â10
24 M cystamine or 10 24 M valsartan for 30 min. Then, the mesenteric arterioles were moved to HGNT buffer (20 mM HEPES, 150 mM NaCl, 10% glycerin, 20 mM NaH 2 PO 4 , 0.1% Triton X-100, pH 7.4), including the Complete protease inhibitor cocktail (Roche), and sonicated on ice. Protein concentrations in the buffer were determined by the Bradford's method.
Western blot analysis
Equal amounts of protein from mesenteric arterioles were applied to SDS-polyacrylamide gels (5-20% gradient gels). Protein was transferred to PVDF membranes (Bio-Rad Laboratories). After blocking for 1 h, membranes were incubated with anti-AT 1 antibody at 48C overnight, followed by 1 h incubation with the secondary antibody. Immunoreactive bands were detected using the ECL Plus detection system (Amersham Pharmacia Biotech).
In situ transglutaminase activity
To assess the effect of aldosterone on intracellular transglutaminase activity, the experiment was carried out on the mouse VSMC line (MOVAS) (American Type Culture Collection, #CRL-2797) and the mesenteric arteriole networks isolated from WT mice. MOVAS cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin (complete medium) at 378C under 5% CO 2 , and subcultured every 5-7 days with trypsin-EDTA. The media in all cultures were renewed every 2-3 days. Then, the cells were incubated with serum-free DMEM for 12 h prior to experiments. The mesenteric arteriole networks isolated from WT mice were minced and washed in cold PBS. Then, minced mesenteric arterioles were equilibrated in albumin-PSS for 30 min at 378C. MOVAS cells and minced mesenteric arterioles were labelled with 2 mM 5-(biotinamido)pentylamine (Pierce), a biotinylated polyamine, for 60 min at 378C under 5% CO 2 , and then treated with 10 27 M aldosterone for 10 min with or without pre-treatment with transglutaminase inhibitors for 30 min. To test the calcium dependency of transglutaminase activation, in another set of experiments, MOVAS cells were incubated with 10 25 M BAPTA-AM for 30 min, followed by 2 mM biotinylated polyamine for 60 min, and then treated with 10 27 M aldosterone without extracellular calcium for 10 min. The cells and minced mesenteric arterioles were harvested and sonicated on ice, and protein concentrations were determined. Intracellular transglutaminase activity was quantified by measuring the presence of incorporated 5-(biotinamido)pentylamine into proteins by a microplate assay using horseradish peroxidase-conjugated streptavidin and the TMB colour-developing kit (Pierce), as described by Zhang et al. 21 Absorbance values measured at 450 nm were calculated as a percentage of basal absorbance (that is, with no drug additions) within a given group of samples.
Assay for angiotensin II
Isolated mesenteric arteriole networks from WT mice were incubated in albumin-PSS at 378C for 30 min, and aliquots were sampled to measure the basal release of angiotensin II. After treatment with aldosterone at 10 27 M for 10 min, the albumin-PSS was sampled again to measure the angiotensin II level. The concentration of angiotensin II was directly measured by radioimmunoassay.
Data analysis
All data are presented as the per cent changes in vessel diameter from the baseline and are expressed as means + SEM. The changes in the mesenteric arteriolar diameter in response to aldosterone were analysed by analysis of variance (ANOVA) followed by Scheffe's post hoc test. Comparison of the responses of the mesenteric arteriolar diameter to different agents or treatments was performed using two-way ANOVA. The transglutaminase activities were compared using ANOVA followed by Scheffe's post hoc test. The change in angiotensin II concentration after treatment of the mesenteric arteriole network with aldosterone was analysed using a paired t-test. Significance was accepted at P , 0.05. The authors had full access to the data and take the responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
3.1. Effect of aldosterone on the mesenteric arteriolar diameter and the role of AT 1 receptor in it Figure 1A shows the time course of aldosterone-induced vasoconstriction in the mesenteric arterioles (n ¼ 10). Aldosterone (10 26 M) produced a rapid vasoconstrictor effect. Notable vasoconstriction occurred at 10 s, and the response reached the maximum within a few minutes in almost every experiment. Figure 1B shows the dose dependency of the vasoconstrictor effect of aldosterone in WT mice. Aldosterone at doses .10 212 M caused a significant and dose-dependent vasoconstrictor effect with a maximum diameter change of 28.6 + 0.3% from the baseline at a dose of 10 26 M (n ¼ 54, P , 0.001). A representative example showing the dose-dependent, vasoconstrictor effect of aldosterone is shown in Figure 1C .
Pre-treatment with spironolactone or eplerenone did not affect these aldosterone-induced vasoconstrictor effects, and the maximal diameter changes induced by aldosterone before and after treatment with spironolactone were 28.6 + 1.0 and 28.3 + 1.0%, respectively (n ¼ 7), while those before and after treatment with eplerenone were 29.5 + 0.5 and 29.1 + 0.7%, respectively (n ¼ 7) (Figure 2A and B) .
When vasoconstrictor responses were compared between endothelium-intact and endothelial-denuded arterioles (n ¼ 6), there was no significant difference between them ( Figure 2C) . Figure 2D shows the effect of hydrocortisone on the mesenteric arteriolar diameter: only a negligible vasoconstrictor response was noted. The GR antagonist RU486 did not influence the vasoconstrictor effect of aldosterone (diameter change, 28.8 + 0.5 vs. 28.4 + 0.7% at 10 26 M aldosterone, P ¼ NS) (n ¼ 6) ( Figure 2D) .
We recently showed that the vasoconstrictor effect of aldosterone in rat coronary arterioles is mediated via AT 1 receptors.
14 As shown in Figure 3A and B, either valsartan or candesartan abolished the vasoconstrictor effect of aldosterone. The maximal diameter changes induced by aldosterone before and after treatment with valsartan at 10 26 and 10 24 M were 28.8 + 0.5 and 23.5 + 0.7%, respectively, for 10 26 M (n ¼ 6), and 29.2 + 0.9 and 22.2 + 0.4%, respectively, for 10 24 M (n ¼ 8), whereas those before and after candesartan treatment were 28.9 + 0.6 and 23.4 + 1.1%, respectively (n ¼ 7) (all P , 0.05). To further confirm the participation of AT 1 receptors in aldosterone's vasoconstrictor effect, we compared the effects of aldosterone between WT and AT 1 aKO mice. In contrast to WT mice, only a negligible vasoconstrictor effect was observed in the mesenteric arterioles of AT 1 aKO mice (n ¼ 7) (Figure 3C ), despite the fact that the vasoconstrictor response to 40 mM KCl was similar between WT (diameter change, 241.5 + 2.0) and AT 1 aKO mice (242.1 + 4.6) (P ¼ NS). The AT 2 receptor blocker PD123319 did not influence aldosterone-induced vasoconstriction (diameter change, 29.6 + 0.6 vs. 29.0 + 0.7% at 10 26 M aldosterone, P ¼ NS) (n ¼ 7) (Figure 3D ).
Mechanism for the vasoconstrictor effect of aldosterone
We first examined the possibility that aldosterone produces a vasoconstrictor effect by increasing the level of endogenous angiotensin II in the mesenteric arterioles. As shown in Figure 4A , angiotensin II (. 10 29 M) caused a significant and dose-dependent vasoconstrictor effect, like aldosterone, on the mesenteric arterioles of WT mice (P , 0.05), and co-administration of angiotensin II and aldosterone resulted in an additional effect to that induced by angiotensin II alone (P , 0.05, n ¼ 8). Benazepril showed no influence on the vasoconstrictor effect of aldosterone, and the maximal diameter changes before and after treatment with benazepril were 27.0 + 0.7 and 27.1 + 0.6%, respectively (n ¼ 7) ( Figure 4B ). When the effect of aldosterone on the release of angiotensin II from the mesenteric arteriole network was examined, no significant increase in angiotensin II concentration was observed after treatment with aldosterone ( Figure 4C) .
We then examined the role of intracellular transglutaminase activation in the effect of aldosterone. As shown in Figure 5A , both cystamine and monodansyl cadaverine inhibited the vasoconstrictor effect of aldosterone in WT mice. The maximal diameter changes induced by aldosterone before and after treatment with cystamine were 27.5 + 0.6 and 20.4 + 0.4%, respectively (P , 0.05, n ¼ 7), whereas those before and after monodansyl cadaverine treatment were 29.2 + 1.3 and 22.9 + 1.1%, respectively (P , 0.05, n ¼ 6). Neither cystamine nor monodansyl cadaverine affected the vasoconstrictor effect of angiotensin II ( Figure 5B ). Figure 6A illustrates the representative bands for AT 1 protein in the presence or absence of aldosterone in the mesenteric arterioles (western blot analysis). There was a single immunoreactive band for AT 1 protein at 50-60 kDa in the absence of aldosterone. Higher molecular weight immunoreactive bands for AT 1 at 100-120 kDa emerged at 10 min after treatment with aldosterone. Pre-treatment with cystamine and valsartan inhibited the emergence of these high-molecular-weight immunoreactive bands for AT 1 in response to aldosterone.
AT 1 receptor dimer formation induced by aldosterone

Effect of aldosterone on in situ transglutaminase activity
As shown in Figure 6B and C, aldosterone increased the levels of pentylamine-incorporated protein, a measure of in situ transglutaminase activity, by 2.5 + 0.2-fold in MOVAS cells (P , 0.05) and by 1.2 + 0.1-fold in the mesenteric arterioles (P , 0.05) compared with a control experiment without aldosterone (P , 0.05 vs. control). Pretreatment with the transglutaminase inhibitors cystamine or monodansyl cadaverine inhibited this increase (P , 0.05). In calcium-free conditions, aldosterone did not influence the transglutaminase activity.
Discussion
Wehling et al. 22 first showed unequivocal rapid effects of aldosterone, which were neither mimicked by cortisol nor blocked by spironolactone, and postulated that these nongenomic effects were mediated by a plasma membrane receptor distinct from the classical MR. In the present study, aldosterone was found to cause vasoconstriction in the resistance arterioles within a few minutes. This effect of aldosterone was not mimicked by hydrocortisone, and was unaffected by MR and GR antagonists, strongly suggesting that the vasoconstrictor effect of aldosterone is non-genomic and independent of classical MR. However, the mechanism underlying this non-genomic vasoconstrictor effect of aldosterone remains unclear.
We recently demonstrated that aldosterone induces a rapidly occurring vasoconstrictor effect in isolated rat coronary arterioles, and that this effect is not inhibited by spironolactone, but by AT 1 receptor blockers.
14 Aldosterone potentiates the rennin-angiotensin system by some mechanism(s). It was shown that aldosterone increases local generation of angiotensin II by up-regulation of ACE mRNA expression and its activity. 23, 24 This raises the possibility that the present vasoconstrictor effect of aldosterone might be attributed to the generation of endogenous angiotensin II. However, the effect of aldosterone occurred too rapidly to be caused by de novo synthesis of angiotensin II, and the transient stimulation with aldosterone did not increase angiotensin II release from mesenteric arteries. In addition, aldosterone-induced vasoconstriction was unaffected by the ACE inhibitor benazepril. These findings all suggest that locally generated endogenous angiotensin II via ACE activation is not involved in the present vasoconstrictor effect of aldosterone. Although a recent study showed the existence of a non-ACE-dependent angiotensin II-forming system, 25 the involvement of this non-ACEdependent system in the action of aldosterone was not established. Furthermore, we demonstrated that angiotensin II caused vasoconstriction, and that the addition of aldosterone resulted in a greater degree of vasoconstriction, indicating that the signalling pathway mediating aldosterone-induced vasoconstriction is not necessarily the same as that involving angiotensin II. It should be pointed out that aldosterone-induced vasoconstriction was small compared with that induced by angiotensin II. Generally, Figure 2 (A and B) Effects of spironolactone and eplerenone on aldosterone-induced changes in mesenteric arteriolar diameter in wild-type mice. Neither spironolactone nor eplerenone influenced aldosterone's effect (P ¼ NS, two-way ANOVA). (C ) Effect of aldosterone on the mesenteric arteriolar diameter in endothelium-denuded arterioles. There was no difference in the vasoconstrictor effects between endothelium-intact and endothelium-denuded vessels (P ¼ NS, two-way ANOVA). (D) Effects of hydrocortisone on mesenteric arteriolar diameter in wild-type mice, and the effect of the GR antagonist RU486 on the aldosterone-induced vasoconstrictor effect in wild-type mice. RU486 showed no influence on aldosterone's effect (P ¼ NS, two-way ANOVA).
80% of classical receptor signalling occurs over 2 orders of ligand magnitude, and therefore the aldosterone's vasoconstrictor effect was atypical. The mechanism of AT 1 signalling induced by aldosterone seems not to be mediated via a classical ligand-receptor binding.
Various in vivo/vitro data have shown that aldosterone interacts with angiotensin II signalling via a non-genomic mechanism(s). Chai et al. 26 showed that aldosterone potentiated the vasoconstrictor effect of angiotensin II in the coronary arteries, and that this effect was not blocked by spironolactone. Min et al. 27 also reported that the synergistic effect of aldosterone and angiotensin II on the mitogenic response in VSMCs (within 15 min) was inhibited by the AT 1 receptor blocker olmesartan, but not by spironolactone. 27 Therefore, we further investigated the role of AT 1 receptors in the vasoconstrictor effect of aldosterone.
The present results clearly show that the blockade of AT 1 receptor activation by valsartan or candesartan suppresses the vasoconstrictor effect of aldosterone. Furthermore, as shown by the experiments in AT 1 aKO mice, a genetic deletion of the AT 1 a receptor blocked aldosterone-induced vasoconstriction. It should be pointed out that there are two pharmacologically indistinguishable subtypes of angiotensin II receptor, AT 1 and AT 2 receptors, and AT 1 receptors can be further subdivided into AT 1 a and AT 1 b subtypes in mice. In this study, we examined the effect of aldosterone only in AT 1 a knockout mice, but not in AT 1 b or AT 2 knockout mice. It was reported that systemic blood pressure was comparable in AT 1 b receptor knockout mice and WT mice. 28 Regarding the role of AT 2 receptor in the present vasoconstrictor effect of aldosterone, the AT 2 receptor blocker PD123319 had no influence on this effect of aldosterone. Taken together, these findings suggest that AT 1 a receptors are key mediators in the signal transduction pathway of aldosterone, and their activation is essential for aldosterone-induced, non-genomic vasoconstriction.
AT 1 receptors are activated not only by angiotensin II, but also by other mechanisms such as mechanical stress or receptor dimerization. 15, 16 Growing evidence suggests that receptor homo-and heterodimerization specifically modify the signalling downstream of individual receptor subtypes. AT 1 receptors forms heterodimers with other receptors, such as bradykinin B 2 receptors, 29 angiotensin II type 2 receptors, 30 b 2 -adrenergic receptors, 31 and dopamine D 1 receptors. 32 For example, heterodimerization of the AT 1 receptor with bradykinin B 2 receptor specifically enhances angiotensin II-stimulated signalling in pre-eclampsia. 33 Recently, AbdAlla et al. 16 demonstrated that the intracellular factor XIIIA transglutaminase cross-links with agonist-induced AT 1 receptor homodimers, and that these cross-linked dimers display enhanced AT 1 signalling and desensitization. Therefore, we investigated the involvement of AT 1 receptor dimerization in the aldosterone-induced non-genomic vasoconstriction. The results showed that treatment of mesenteric arterioles with aldosterone leads to the generation of AT 1 dimers. We further showed that pre-treatment with the transglutaminase inhibitor cystamine not only blocked the dimerization of AT 1 receptors, but blunted the vasoconstrictor effect of aldosterone, while showing no influence toward the vasoconstrictor effect of angiotensin II. Moreover, an in situ transglutaminase activity assay showed that aldosterone increased intracellular transglutaminase activity. These findings suggest that the activation of AT 1 receptors by aldosterone is dependent on the dimerization of these receptors via the activation of intracellular transglutaminase, and is clearly distinct from the activation of AT 1 receptors induced by angiotensin II binding. Transglutaminase is a calciumdependent enzyme that catalyzes the posttranslational modification of proteins by transamidation of specific polypeptide-bound glutamine residues. 34 Wehling et al.
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reported that aldosterone non-genomically increases the intracellular calcium level in VSMCs, which is consistent with our finding of aldosterone-induced, calcium-dependent transglutaminase activation. Valsartan and candesartan were recently described as inverse agonists of AT 1 receptors, 15, 36 blocking AT 1 signalling by inducing a conformational change to an inactive structure. 36, 37 In this study, valsartan not only blocked aldosterone-induced vasoconstriction, but also the formation of AT 1 dimers. This indicates that the inverse agonist-induced conformational change in AT 1 receptors may contribute to the inhibition of the formation of AT 1 dimers.
Implications
In addition to the regulation of salt and water balance, aldosterone has been shown to exert some deleterious effects, including cardiovascular remodelling, endothelial dysfunction, and renal injury. 38 With the use of MR antagonists, the randomized aldactone evaluation study (RALES) and eplerenone neurohormonal efficacy and survival study (EPHESUS) established the beneficial effects of chronic blockade of aldosterone on morbidity and mortality in patients with chronic heart failure. 39 , 40 Recently, we reported that aldosterone caused a significant, mild degree of vasoconstriction in rat coronary arterioles, which may result in the exacerbation of myocardial ischaemia and ventricular function. The present study clearly demonstrates that this vasoconstrictor effect of aldosterone is dependent on AT 1 receptors, and that their activation may be mediated by receptor dimerization. Importantly, this effect of aldosterone was not blocked by MR antagonist, but by AT 1 receptor blockers. AT 1 receptor blockers are among the most beneficial drugs that improve the prognosis of patients with chronic heart failure. An inhibitory effect of AT 1 receptor blockers on aldosterone-induced vasoconstriction may partly underlie some of the benefits of these drugs.
Limitation
Despite this novel activation mechanism of AT 1 receptors as the initial signalling event in the vasoconstriction of resistance arterioles induced by aldosterone, the upstream signalling pathway leading to transglutaminase activation and dimerization of AT 1 receptors still remains unclear. Furthermore, we did not identify which type of transglutaminase is involved, and we did not show which out of homodimers and heterodimers including the AT 1 receptor is induced by aldosterone. Further biochemical investigations are needed. The vessels were pressurized from the luminal side without flow, and each drug was administered to the bath side. This seems to be different from the physiological condition in which drugs affect both inner and outer sides.
